Three acronyms showed up in pharma marketing decks this year, and most of them are being sold as competitors. GEO, AEO, LLMO. A vendor pitches one, an agency pitches another, and a brand team ends up convinced it has to choose, or worse, buy all three from three different people.
They are not three things. They are one job described at three altitudes. GEO is the strategy, AEO is the format, LLMO is the engine layer, and in pharma the whole stack only works if it sits on a compliance backbone that none of the generic playbooks mention. Indegene framed exactly these three terms as the new search optimization trinity for pharma, and the framing is right. The marketing of it as three separate purchases is what is wrong.
What follows is what each term means, where pharma is different, and the concrete method that turns the vocabulary into work you can do on Monday.
The three terms, defined
Each acronym answers a different question about the same problem: how does a brand show up when a machine answers a question instead of returning links.
GEO, generative engine optimization. This is the umbrella. GEO is the practice of getting your content surfaced and cited inside an AI-generated answer, on any engine, for any audience. It is the strategy layer. When someone says "we need an AI search strategy," they mean GEO, whether they use the word or not. The other two terms live underneath it.
AEO, answer engine optimization. This is the format layer. AEO is about structuring your content so a machine can lift a clean, direct answer out of it: question-and-answer blocks, plain declarative sentences, one claim per sentence, schema markup that tells the engine what it is reading. AEO is the part of GEO that touches your actual content. If GEO is the goal, AEO is most of the craft.
LLMO, large language model optimization. This is the engine layer. LLMO is about how a specific model retrieves, weighs, and cites sources, and how your brand fares inside that mechanism. It is the most technical of the three and the least uniform, because every engine behaves differently. The same content can win in one model and vanish in another, and LLMO is the discipline of understanding why.
So the relationship is nested, not parallel. You do GEO by doing AEO well across the LLMs your audience uses. Anyone selling them to you as three separate programs is selling you three invoices for one outcome.
Why pharma breaks the generic playbook
Every GEO guide written for e-commerce or B2B SaaS assumes the same thing: more visibility is good, full stop. Get cited more, win more. For a regulated message that assumption is not just incomplete, it is dangerous.
The tactics that win at GEO are now academically established. A peer-reviewed study from researchers at Princeton, IIT Delhi, and Georgia Tech tested optimization methods across a benchmark of 10,000 queries and found that the right approach can boost a source's visibility in generative engine responses by up to 40 percent. The five most effective methods were citing sources, adding quotations, adding statistics, improving fluency, and adopting an authoritative voice. Two of those, adding statistics and adopting an authoritative voice, are exactly the moves that, done carelessly, manufacture an efficacy claim. The generic playbook tells you to be more persuasive. In pharma, persuasion without fair balance is a violation.
GEO does not let pharma skip compliance. It raises the stakes on it. Evertune's pharma GEO playbook puts it plainly: GEO does not replace compliance, it amplifies the need for it. Every tactic that makes your content easier for a machine to lift also makes it easier for the machine to lift it out of context, strip the safety language, and present an efficacy line as a free-standing fact. The optimization and the compliance are the same motion in pharma. You cannot do one without the other and stay legal.
This shift has gone further in health than in any other category. AI Overviews appear in roughly 51 percent of healthcare searches, the highest rate of any industry, according to a WebFX study of 130,070 health queries. The same study found the machine answer triggers more often on longer, more informational questions, which is precisely the shape of what patients and clinicians ask. And pharma is the part of health with the strictest rules about what that answer is allowed to say.
The method: map your prompt universe first
Before you optimize a word of content, map a prompt universe.
A prompt universe is the full set of questions your audiences actually ask a machine about your therapeutic area. Not your campaign headlines. Not your SEO keywords. The real, conversational, messy questions a patient types into ChatGPT at 11pm and a physician fires into a clinical answer engine between appointments. Evertune's pharma playbook recommends defining 300 to 600 prompts across patient, payer, and HCP audiences and tracking how often the brand appears in the AI-generated answers to them.
That range fills up fast. A single drug has dozens of patient questions (what is it for, what are the side effects, can I take it with my other medication, how much does it cost, is there a generic), a parallel set of payer questions (what is the evidence, what does it cost the plan, how does it compare on outcomes), and a deeper set of HCP questions (mechanism, dosing in renal impairment, contraindications, head-to-head data, guideline placement). Cross those audiences with the variations in how people actually phrase things and you are at several hundred prompts fast. That set is your measurable surface. Everything downstream optimizes against it.
The prompt universe also forces a useful discipline: it is built per audience, and the answers are graded per audience. A patient prompt and an HCP prompt about the same drug have different correct answers and different fair-balance requirements. A prompt universe that does not separate them will average away the exact failures you most need to see.
The method: the engines do not behave the same
Once you have the prompt universe, run it across the engines your audience uses, and expect them to disagree. This is the LLMO layer made concrete. The same prompt, the same brand, different answers, because each model retrieves and cites differently.
The patterns are understood well enough to plan around. ChatGPT leans heavily on earned media and established third-party sources. Perplexity favors fresh content and whitelisted domains, rewarding recency and authority signals. Google AI Overviews behave differently again, and the medical answer engines in your therapeutic area have their own source preferences entirely. A brand that is strong in one can be invisible in another, and the only way to know is to measure each separately. Evertune's playbook documents exactly this split in engine citation behavior, and it is the reason a single "are we in AI search" check is meaningless. There is no single AI search. There are several, and they reward different things.
The practical consequence: LLMO is not a setting you toggle. It is per-engine reconnaissance. You learn that one engine cites your corporate site, another cites a patient forum, a third cites a years-old summary that drops your safety section, and you optimize each surface accordingly. That is why the prompt universe runs across engines, not against one.
The method: structure the approved sentence so the machine prefers it
This is the AEO layer, the content work. The goal is narrow: make your correct, approved answer the easiest correct answer for a machine to lift.
The Princeton research already told you the levers, cite sources, add statistics, structure for fluency, write with authority. The pharma move is to apply every one of those inside fair balance. Indegene's recommendation is concrete: publish MLR-approved drug information in a structured question-and-answer format aligned to physicians' real clinical information needs. That single instruction does most of the AEO job at once. A question-and-answer block is the format answer engines lift most cleanly. MLR-approved is the constraint that keeps the statistics and authoritative voice from drifting into an unsupported claim. Aligned to clinical needs is the prompt-universe discipline made into content.
Two more structural moves matter in pharma specifically. First, embed full context. Evertune's playbook recommends including the complete picture, indications, dosage, and safety warnings, in the source content to reduce hallucination. When the safety language travels with the efficacy claim in the same structured block, the engine is far less likely to lift the benefit and drop the risk. Fair balance becomes a hallucination control, not just a regulatory chore. Second, broaden your source footprint beyond the corporate site and implement the schemas that tell engines what they are reading: MedicalCondition, Drug, FAQ. The engine that does not understand your page will not cite it cleanly.
None of this is keyword stuffing. It is the opposite. It is making the approved sentence so clean, so well-marked, and so completely contextualized that a fluent machine has no reason to paraphrase around it.
A worked example: Varigel across the stack
Take a fictional brand, Varigel, approved for one narrow indication with a known contraindication in patients on a common comorbidity medication. Walk it through the three layers.
GEO is the goal: when patients, payers, and HCPs ask a machine about Varigel, Varigel should appear, accurately, with its safety language intact. To pursue it, the team builds a prompt universe of around 400 prompts. Patient prompts ("is Varigel safe with my blood pressure medication"), payer prompts ("what is the cost-effectiveness evidence for Varigel"), HCP prompts ("Varigel dosing in renal impairment," "Varigel versus standard of care"). That set is the measurable surface.
LLMO is the reconnaissance. The team runs all 400 prompts across the engines its audiences use and finds disagreement, as expected. One engine cites Varigel's approved label and answers cleanly. Another, leaning on a years-old conference abstract, mentions a "commonly discussed" second use the brand never promoted, off-label drift, generated unprompted. A third, summarizing efficacy from a source that skipped the safety section, omits the contraindication entirely. Three engines, three different exposures, only visible because the prompt universe ran across all of them.
AEO is the fix. For each failing answer the team traces the citation to its source, then publishes a structured, MLR-approved question-and-answer block that embeds the full context, the indication, the dosing, and the contraindication together, so the safety language travels with every efficacy statement. They mark it up so the engines understand it, and they broaden the footprint so the clean source outranks the ambient noise the engines were leaning on. Then they measure the same 400 prompts again and watch which engines now lift the approved answer.
Notice what governs every step. The "winning" tactic, the one the generic playbook would cheer, is the structured authoritative answer. In pharma that exact tactic is a compliance event. The question-and-answer block has to be the approved one. The statistics have to be the cleared ones. The authoritative voice has to carry fair balance. GEO did not let Varigel skip MLR. It made MLR the load-bearing wall.
Where the vocabulary leaves you
GEO, AEO, and LLMO are not a menu. They are a strategy, a format, and an engine layer, stacked, and in pharma they share a foundation the generic guides leave out: every optimization move is also a regulatory move, and the two cannot be done separately.
That is the seam most brands cannot cross, because the inside and the outside have never been connected. The team that approves the message has no view of what the machines say. The agency that might measure the machines has no authority over the approved message. So the prompt universe gets mapped by one group, the content gets approved by another, and the drift gets found late, in a screenshot someone forwards in alarm.
Juncture is built for that join. Inside, Pre-check compares every asset against the approved label before MLR, so the structured, authoritative content you publish for AEO is cleared content, not an accidental claim. Outside, Answer Monitor runs your prompt universe across the engines your audience uses, measures how often the brand appears and whether each mention matches the label, and flags off-label drift the week it surfaces. Both halves are measured against the same approved label, which is the only way the GEO stack stays inside compliance. The optimization and the governance are one motion, exactly as they have to be in pharma.
So skip the three-invoice version. There is one job. Build the prompt universe, measure it across engines, structure the approved sentence so machines prefer it, and keep the whole thing tied to the label that authorizes it. Bring one brand and the real questions your audience asks. We will show you its answer across the engines today, flag the drift already in the wild, and trace it back to the approved sentence that should have been there.
Sources
- Indegene, "GEO vs AEO vs LLMO," 2025. indegene.com
- Evertune, "Generative Engine Optimization (GEO) in Pharma: Six Steps to Owning AI-Driven Health Queries," 2025. evertune.ai
- Aggarwal et al. (Princeton, IIT Delhi, Georgia Tech), "GEO: Generative Engine Optimization," arXiv / KDD 2024. arxiv.org
- WebFX, "AI Overviews in Healthcare," 2025. webfx.com